HighTide Therapeutics' (HKG:2511) subsidiary entered into a strategic co-operation framework agreement with SSY Group's (HKG:2005) subsidiary Shijiazhuang No. 4 Pharmaceutical regarding possible cooperation the fields of metabolic chronic diseases, longevity and anti-aging, a Thursday Hong Kong bourse filing said.
Under the framework agreement, the parties will leverage their individual expertise and advantages for the research and development of solutions for metabolic chronic diseases, longevity, and anti-aging at a global level.
The parties will enter into specific cooperation agreements for formal cooperation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments